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The current definition of iron deficiency based on ferritin <100 ng/ml or transferrin saturation <20% may not accurately reflect the levels of iron within tissue and cells. Therefore, intravenous iron may be administered to heart failure patients who do not require iron supplementation.
Intravenous administration of iron bypasses essential regulatory mechanisms and can cause endothelial damage via the production of reactive oxygen species.
Although iron should be given to patients with heart failure and iron deficiency, sufficient consideration should be given to the route of administration and the potential for adverse effects, especially in non-iron deficient patients.
Further research must be conducted to determine whether changes in the cellular and subcellular distribution of iron in patients with heart failure are compensatory and beneficial or maladaptive and potentiates disease.
SUMMARY
To date, 3 clinical trials have shown symptomatic benefit from the use of intravenous (IV) iron in patients with heart failure (HF) with low serum iron. This has led to recommendations in support of the use of IV iron in this population.
However, the systemic and cellular mechanisms of iron homeostasis in cardiomyocyte health and disease are distinct, complex, and poorly understood. Iron metabolism in HF appears dysregulated, but it is still unclear whether the changes are maladaptive and pathologic or compensatory and protective for the cardiomyocytes. The serum markers of iron deficiency in HF do not accurately reflect cellular and mitochondrial iron levels, and the current definition based on the ferritin and transferrin saturation values is broad and inclusive of patients who do not need IV iron. This is particularly relevant in view of the potential risks that are associated with the use of IV iron. Reliable markers of cellular iron status may differentiate subgroups of HF patients who would benefit from cellular and mitochondrial iron chelation Systemic iron homeostasis is predominantly regulated by the hormone hepcidin and the protein ferroportin 1 (Fpn1), the latter being the only known iron export protein in mammals. The efflux of iron from enterocytes, macrophages, and hepatocytes into the extracellular fluid and, ultimately, into the serum occurs via Fpn1. Hepcidin, which is produced in the liver, binds to Fpn1 and triggers its internalization and lysosomal degradation. Therefore, the ultimate action of hepcidin is to down-regulate the export of iron from enterocytes, hepatocytes, and macrophages into the circulation (Figure 1) .
The production of hepcidin is transcriptionally upregulated in response to an elevated concentration of serum iron, increased tissue iron stores, and in chronic inflammatory states (1) . Ganz et al. (4) demonstrated that even a mild transient increase in the serum iron level after the administration of a dose of oral iron is sufficient to dramatically raise serum hepcidin level within 8 h. In chronic inflammatory states, the increased production of hepcidin diminishes iron release from enterocytes and induces iron trapping within macrophages and hepatocytes, a condition of iron restriction that is the hallmark of the anemia of chronic disease. Furthermore, patients with chronic kidney disease (CKD) have elevated levels of hepcidin, which may be associated with increased atherosclerosis and cardiovascular risk in this population, possibly through intracellular iron sequestration and oxidative stress (5) (6) (7) (8) . Similarly, obesity has been associated with increased hepcidin levels (9) , and the mechanism appears to be through the leptin-mediated increase in the production of hepcidin (10) .
Conversely, in conditions of enhanced erythropoiesis or iron deficiency (ID), the production of hepcidin is down-regulated, allowing more iron to be released into the serum from intestinal epithelial cells and from iron stores within macrophages and hepatocytes. In response to endogenous or exogenous erythropoietin (EPO), erythroid precursor cells produce the hormone erythroferrone (ERFE). The main effect of ERFE is the suppression of hepcidin production in the liver to maintain adequate supply of iron to the bone marrow to sustain normal erythropoiesis, which is the most iron-consuming process in the body.
The extracellular iron level is sensed by the hepatocytes and can regulate hepcidin production. After absorption from the intestine and release into the blood through Fpn1, iron binds to Tf. Human cell membrane contains Tf receptors (TfR) that bind to Tf.
The Tf-TfR complex is then internalized, iron is released into the cell, and Tf is recycled back into the serum (3). Transferrin receptor protein 1 (TfR1) plays a crucial role in iron uptake in human cells. Transferrin receptor protein 2, which is mostly found in the liver, is a sensor of the extracellular iron level and is thought to play a role in regulating hepcidin production (1, 11) .
There are 2 main strategies for increasing iron in iron-deficient patients. The first strategy relies on oral iron supplements that can be absorbed naturally in the duodenum and proximal jejunum, a process that is significantly facilitated by the acidic environment of the stomach. The low levels of hepcidin that occur during ID allow the iron to exit the enterocytes and enter the circulation. As serum iron levels are restored to normal, the production of hepcidin in the liver is increased, and further release of iron from the enterocytes is prevented. Because of this feedback mechanism, oral iron supplements are generally safe and rarely, if ever, cause systemic iron overload. The second strategy for iron repletion is via direct IV delivery ( Figures 1 and 2A) . A benefit of this method is that it allows for rapid and significant correction of iron indexes, particularly in instances in which absorption is compromised (e.g., in patients on proton pump inhibitors). However, this method of administration bypasses the aforementioned regulatory mechanisms and can potentially cause local iron overload in endothelial cells and cardiomyocytes via non-Tf-mediated iron uptake ( Figure 2B ). This will be discussed in further detail later.
CELLULAR IRON REGULATION IN THE HEART
Cardiomyocytes, like other cell types, have only one pathway for iron export and that is through Fpn1.
However, there are several ways that iron can enter cardiomyocytes (described later and depicted in Figure 2B ). This makes cardiomyocytes particularly vulnerable to iron overload. Mice with cardiomyocyte-specific deletion of Fpn1 develop a rapid and ultimately fatal dilated cardiomyopathy that is associated with the accumulation of iron inside the cardiomyocytes while the systemic iron level remains unaltered (12) . Hepcidin is also produced in cardiomyocytes. Cardiac hepcidin has important autocrine effects and participates in the autonomous regulation of iron in cardiomyocytes that are distinct from systemic iron regulation (13) . In contrast to systemic hepcidin, the level of cardiac hepcidin increases in iron deficiency to preserve the cellular iron.
Iron uptake by cardiomyocytes primarily occurs through TfR1. Only Tf-bound iron can enter cardiomyocytes via this pathway. Mice lacking TfR1 in the heart die early from a cardiomyopathy that is associated with cardiac ID (14) . Another important pathway for the influx of iron into the cardiomyocytes is through the divalent metal transporter 1 protein 
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Dietary iron is absorbed in the duodenum and transported across the epithelia where it is delivered to Transferrin (Tf). The majority of iron is then either delivered to the bone marrow where it is used in hematopoiesis, or it is stored in the liver. Hepcidin is a hormone released by the liver that prevents iron absorption and release from macrophages when iron stores reach sufficient levels. Although iron absorbed by the gut and bound to Tf is mostly redox inactive, iron administered intravenously enters systemic circulation as unbound iron and can be toxic to cells and tissues through the production of reactive oxygen species. 
DYSREGULATION OF IRON METABOLISM IN HEART DISEASE: EXCESS OR DEFICIENCY?
Some studies have shown that patients with HF are "iron deficient" (19) (20) (21) (22) , and the current society guidelines recommend iron supplementation in HF patients with reduced ejection fraction for symptomatic benefit, regardless of the presence or absence of anemia (Table 1) . However, the etiology of ID in HF and, more importantly, the best method to diagnose this condition in HF are matters of controversy. The current proposed criteria to diagnose ID in HF are serum ferritin <100 ng/ml or serum transferrin saturation (TSAT) <20% (23-26). This definition was originally used in patients with CKD (27, 28) . Because clinical trials of IV iron in HF used the same definition and were associated with a symptomatic benefit, subsequent studies and the current HF guidelines adopted these cutoffs to define ID in HF. However, as The ferritin-TSAT definition had a positive predictive value of 66.7%. Therefore, 33% of the HF patients in this particular cohort who were considered "iron 
IRON SUPPLEMENTATION IN HF
Over the past decade, the effects of iron supplementation on HF have been tested in several studies ( Table 2 ). In the subsequent sections, we Table 1 .
Ghafourian et al. This nonbound iron can react with hydrogen peroxide and generate highly toxic hydroxyl radicals ( Figure 3) . Moreover, ferroptosis, as a nonapoptotic, iron-mediated form of cell death, has been shown to be involved in several cardiovascular processes such as ischemia/reperfusion (I/R) injury and doxorubicin-induced cardiomyopathy (45, 46) .
Interestingly, the administration of an iron chelator in vivo was protective against I/R-induced cardiomyopathy (46) .
The potential toxic effects of increased iron on endothelial cells was demonstrated in a study using an apolipoprotein E-deficient mouse model in which it was shown that the iron load was associated with the progression of atherosclerosis via inducing a proinflammatory state (47) . In another study, the restriction of dietary iron in a similar mouse model resulted in significant inhibition of atherosclerosis (48) . IV iron has also been shown to be associated with markers of endothelial dysfunction (49) (50) (51) . In a human study, the administration of IV iron at therapeutic doses to healthy volunteers resulted in transient endothelial dysfunction and was associated with a significant rise in NTBI and a biomarker of oxidative stress (52) . 
IS ORAL IRON EFFECTIVE IN HF?
The only study to date to compare IV iron versus oral iron in HF was terminated prematurely because of competing trials and insufficient funding (43) . In this study (IRON-HF), 23 anemic HF patients with LVEF <40%, TSAT <20%, and ferritin <500 ng/ml were 
IRONOUT-HF (Iron Repletion Effects on Oxygen
Uptake in Heart Failure) was a National Institutes of (69) (70) (71) . Ferric citrate has emerged as another effective oral formulation of iron. A randomized clinical trial in the CKD population with ID anemia showed that 16 weeks of therapy with this oral formulation was associated with significant increase in iron indexes (72) .
DOSING SCHEDULE OF ORAL IRON. Emerging evidence suggests that the conventional schedule of 2 or 3 times daily of oral iron therapy could lead to a rapid and transient response in hepcidin production and result in limited absorption of the subsequent dose of oral iron (73) . Intriguing findings from an RCT suggest that oral iron supplementation on alternate days and in single doses can optimize iron absorption and might be the preferred dosing regimen (74) .
IRON CHELATION IN
CARDIOVASCULAR DISEASE
There is no mechanism for the removal of excess body 
CONCLUSIONS
The human body has evolved to conserve iron. It has also developed meticulous regulatory mechanisms to protect cells from the toxic effects of free iron by regulating its absorption and storage. It is still unclear if the apparent dysregulation of iron metabolism in cardiac disease is maladaptive or a regulatory effort of the body to maintain cellular iron homeostasis. While the pursuit of understanding iron metabolism in cardiac health and disease is continued, the use of IV iron should be considered cautiously and limited to patients with true iron deficiency.
